Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lannett Eyes Insulins Opportunity And Advances Respiratory Assets

CEO Tim Crew Sets Out Expectations For Pipeline As Firm Licenses Insulin Pen Patent

Executive Summary

Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.

You may also be interested in...



Lilly Gets Second Interchangeable Insulin Glargine In US

Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.

Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

Lannett Sees Boost From Adderall Shortages And Pricing Reprieve

In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel